Search results for " OUTCOME"

showing 10 items of 4574 documents

Proper assignation of reactivation in a COVID-19 recurrence initially interpreted as a reinfection

2021

A 77-year-old-male (Case R) who had had a previous diagnosis of mild COVID-19 episode, was hospitalized 35 days later. On Day 23 post-admission, he developed a second COVID-19 episode, now severe, and finally died. Initially, Case R COVID-19 recurrence was interpreted as a reinfection due to the exposure to a SARS-CoV-2 RT-PCR-positive room-mate. However, whole-genome-sequencing indicated that case R recurrence corresponded to a reactivation of the strain involved in his first episode. Case R reactivation had major consequences, leading to a more severe episode, and causing a subsequent transmission to another two hospitalized patients, one of them with fatal outcome.

0301 basic medicineMalePediatricsmedicine.medical_specialty2019-20 coronavirus outbreakFatal outcomeCoronavirus disease 2019 (COVID-19)Hospitalized patientsSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Antibodies Viral03 medical and health sciences0302 clinical medicineNosocomial transmissionRecurrencemedicineImmunology and AllergyHumans030212 general & internal medicineAgedFirst episodeWhole Genome Sequencingbusiness.industrySARS-CoV-2Nosocomial transmissionBrief ReportCOVID-19Reactivation030104 developmental biologyInfectious DiseasesAcademicSubjects/MED00290ReinfectionbusinessWGS
researchProduct

Early and rapidly progressing respiratory failure in a patient with amyotrophic lateral sclerosis: when FVC% is misleading

2018

Introduction Respiratory failure is the leading cause of death in amyotrophic lateral sclerosis (ALS) [1]. The involvement of respiratory function is a negative predictor of survival, which can be in part overcome by a prompt initiation of non-invasive mechanical ventilation (NIV). Seated forced vital capacity (FVC%) is a widely used measure to monitor respiratory function, and it is often taken as a surrogate outcome measure in clinical trials. However, it may be within a normal range in ALS patients with respiratory dysfunction [2]. Here we report on a case of an ALS patient with a rapidly evolving respiratory insufficiency, despite a rather normal FVC%. Case presentation The patient, a 6…

0301 basic medicineMalePediatricsmedicine.medical_specialtyNeurologyDermatologyDiagnosis Differential03 medical and health sciencesFEV1/FVC ratio0302 clinical medicineFatal OutcomeMedicineAmyotrophic lateral sclerosisNeuroradiologyAgedbusiness.industryDisease progressionGeneral Medicinemedicine.diseasePsychiatry and Mental health030104 developmental biology030228 respiratory systemRespiratory failureDisease ProgressionNeurology (clinical)NeurosurgeryDifferential diagnosisbusinessRespiratory InsufficiencyAmyotrophic Lateral SclerosiHuman
researchProduct

Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic an…

2016

Objectives: We utilized the database of the Defining Antibiotic Levels in Intensive care unit patients (DALI) study to statistically compare the pharmacokinetic/pharmacodynamic and clinical outcomes between prolonged- infusion and intermittent-bolus dosing of piperacillin/tazobactam and meropenem in critically ill patients using inclusion criteria similar to those used in previous prospective studies. Methods: This was a post hoc analysis of a prospective, multicentre pharmacokinetic point-prevalence study (DALI), which recruited a large cohort of critically ill patients from 68 ICUs across 10 countries. Results: Of the 211 patients receiving piperacillin/tazobactam and meropenem in the DAL…

0301 basic medicineMalePenicillanic Acidintensive care unitlaw.inventionthienamycin derivative abdominal infection[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseaseslawcentral nervous system infectioncreatinine clearancePharmacology (medical)Infusions IntravenouProspective StudiesInfusions IntravenousProspective cohort studyTazobactam Drug CombinationAged; Anti-Bacterial Agents; Blood Chemical Analysis; Critical Illness; Female; Humans; Infusions Intravenous; Intensive Care Units; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin Tazobactam Drug Combination; Prospective Studies; Thienamycins; Treatment Outcome; Pharmacology; Microbiology (medical); Pharmacology (medical); Infectious Diseasescritical illneMicrobial Sensitivity TestadultRespiratory infectionclinical trialMiddle Agedcontinuous infusionanalogs and derivativeIntensive care unit3. Good healthAnti-Bacterial Agentsantiinfective agentintravenous drug administrationIntensive Care Units[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyTreatment OutcomeInfectious DiseasesPiperacillin/tazobactammulticenter study (topic)SOFA scoreFemaletreatment outcome AgedIntravenousprospective studyHumanmedicine.drugsurvival rateMicrobiology (medical)medicine.medical_specialtyInfusionspost hoc analysirespiratory tract infectionCritical IllnessAged; Anti-Bacterial Agents; Blood Chemical Analysis; Critical Illness; Female; Humans; Infusions Intravenous; Intensive Care Units; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Prospective Studies; Thienamycins; Treatment Outcome; Pharmacology; Pharmacology (medical); Infectious Diseases030106 microbiologybloodstream infectionMicrobial Sensitivity Testsminimum inhibitory concentrationpiperacillin plus tazobactamMeropenemTazobactamArticle03 medical and health sciencescritically ill patientInternal medicineAnti-Bacterial AgentmedicineSequential Organ Failure Assessment ScoreHumansThienamycinsurvival timeblood analysiAgedPiperacillinPharmacologybusiness.industryBlood Chemical AnalysiMeropenemmajor clinical studySurgeryProspective Studiemulticenter studyPharmacology; Pharmacology (medical); Infectious Diseases[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/PharmacologyThienamycinspiperacillin tazobactam drug combinationurinary tract infectionbusinessBlood Chemical AnalysisPiperacillin
researchProduct

Increased Symmetric Dimethylarginine Level Is Associated with Worse Hospital Outcomes through Altered Left Ventricular Ejection Fraction in Patients …

2017

International audience; Objectives: We aimed to investigate whether SDMA-symmetric dimethylarginine-the symmetrical stereoisomer of ADMA-might be a marker of left ventricular function in AMI.Background: Asymmetric dimethylarginine (ADMA) has been implicated in the prognosis after acute myocardial infarction (AMI) and heart failure (HF).Methods: Cross sectional prospective study from 487 consecutive patients hospitalized 2, and death.Results: Patients were analysed based on SDMA tertiles. Sex, diabetes, dyslipidemia, and prior MI were similar for all tertiles. In contrast, age and hypertension increased across the tertiles (p<0.001). From the first to the last tertile, GRACE risk score was e…

0301 basic medicineMalePhysiologyPerformanceMyocardial Infarctionlcsh:MedicineBlood PressureChronic Heart-Failure030204 cardiovascular system & hematologyVascular MedicineBiochemistryVentricular Function Leftchemistry.chemical_compound0302 clinical medicineChronic Kidney DiseaseMedicine and Health SciencesCoronary Heart DiseaseDiseaseMyocardial infarctionProspective cohort studylcsh:ScienceMultidisciplinaryFramingham Risk ScoreEjection fractionAsymmetric DimethylarginineNeurochemistryMiddle AgedMetaanalysis[ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemPrognosisArteryHospitals3. Good healthTreatment OutcomeImpactNephrologyHypertensionCardiologyFemaleAnatomyNeurochemicalsResearch ArticleGlomerular Filtration Ratemedicine.medical_specialtyCardiologyRenal functionNitric OxideArginine03 medical and health sciences[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemInternal medicinemedicineHumansRenal Insufficiency ChronicMortalityAgedHeart FailureRenal Physiologybusiness.industrylcsh:RBiology and Life SciencesRenal SystemMarkermedicine.diseaseRenal-Function030104 developmental biologychemistryHeart failurelcsh:QAsymmetric dimethylargininebusinessDyslipidemiaNeuroscience
researchProduct

Effects of transcranial random noise stimulation combined with Graded Repetitive Arm Supplementary Program (GRASP) on motor rehabilitation of the upp…

2019

We evaluated the combined use of transcranial random noise stimulation (tRNS) with the Graded Repetitive Arm Supplementary Program (GRASP) in sub-acute ischemic stroke patients suffering from arm impairment. Eighteen ischemic stroke patients with upper limb disability were randomly assigned to either the GRASP + tRNS or GRASP + Sham stimulation group. Fugl-Meyer Assessment-Upper extremity (FMA-UE) was performed to evaluate upper limb impairment before treatment (T0), after the last stimulation (T1) and after 30 days (T2). At T1 and T2, beneficial effects in the tRNS group correlated with better FMA-UE score than sham stimulation group (p &lt; 0.001) and these results did not correlate to st…

0301 basic medicineMaleStroke rehabilitationmedicine.medical_specialtyNeurologyStimulationPilot ProjectsSub acuteTranscranial Direct Current StimulationUpper Extremity03 medical and health sciencesTranscranial random noise stimulation0302 clinical medicinePhysical medicine and rehabilitationDouble-Blind MethodmedicineHumansGraded Repetitive Arm Supplementary Program (Grasp)Biological PsychiatryPhysical Therapy ModalitiesAgedbusiness.industryGRASPTranscranial random noise stimulation combined (tRNS)BrainRecovery of FunctionCombined Modality TherapyMotor rehabilitationPsychiatry and Mental health030104 developmental biologymedicine.anatomical_structureTreatment OutcomeNeurologyIschemic strokeUpper limbFemaleSettore MED/26 - NeurologiaNeurology (clinical)business030217 neurology & neurosurgery
researchProduct

Yogurt consumption and abdominal obesity reversion in the PREDIMED study.

2016

Yogurt consumption and abdominal obesity reversion in the PREDIMED study. BACKGROUND AND AIMS: Evidence on the association yogurt consumption and obesity is not conclusive. The aim of this study was to prospectively evaluate the association between yogurt consumption, reversion of abdominal obesity status and waist circumference change in elderly. METHODS AND RESULTS: 4545 individuals at high cardiovascular risk were prospectively followed. Total, whole-fat and low-fat yogurt consumption were assessed using food frequency questionnaires. Generalized estimating equations were used to analyze the association between yogurt consumption and waist circumference change (measured at baseline and y…

0301 basic medicineMaleTime FactorsEndocrinology Diabetes and MetabolismMedicine (miscellaneous)0939-4753Logistic regressionDiet MediterraneanDieta mediterràniaRisk FactorsOdds RatioFood scienceProspective StudiesGeneralized estimating equationAbdominal obesityAged 80 and overBioquímica y tecnologíaNutrition and DieteticsAge Factorsfood and beveragesMiddle AgedCircumferenceYogurtDiet RecordsBiochemistry and technologyTreatment OutcomeCardiovascular DiseasesObesity AbdominalOlder adultsObesitatFemalemedicine.symptomWaist CircumferenceCardiology and Cardiovascular Medicinemedicine.medical_specialtyWaistIogurtBioquímica i biotecnologiaabdominal obesity03 medical and health sciencesInternal medicineWeight LossmedicineHumansAgedConsumption (economics)030109 nutrition & dieteticsbusiness.industryPREDIMED studyOdds ratiomedicine.diseaseObesityDietary FatsLogistic ModelsSpainMultivariate AnalysisLinear Modelsbusiness
researchProduct

Dietary Marine ω-3 Fatty Acids and Incident Sight-Threatening Retinopathy in Middle-Aged and Older Individuals With Type 2 Diabetes Prospective Inves…

2016

IMPORTANCE: Diabetic retinopathy (DR) is a devastating complication of individuals with type 2 diabetes mellitus. The retina is rich in long-chain ω−3 polyunsaturated fatty acids (LCω3PUFAs), which are substrate for oxylipins with anti-inflammatory and antiangiogenic properties. Experimental models support dietary LCω3PUFA protection against DR, but clinical data are lacking. OBJECTIVE: To determine whether LCω3PUFA intake relates to a decreased incidence of sight-threatening DR in individuals with type 2 diabetes older than 55 years. DESIGN, SETTING, AND PARTICIPANTS: In late 2015, we conceived a prospective study within the randomized clinical trial Prevención con Dieta Mediterránea (PRED…

0301 basic medicineMaleTime FactorsMediterranean diet2168-6165Type 2 diabetesDieta mediterrànialaw.inventionRandomized controlled triallawRisk FactorsProspective StudiesProspective cohort studyAged 80 and overBioquímica y tecnologíaDiabetisIncidenceDiabetic retinopathyMiddle AgedType 2 DiabetesBiochemistry and technologyTreatment OutcomeFemalemedicine.medical_specialtyBioquímica i biotecnologiaRisk AssessmentOlder IndividualsArticle03 medical and health sciencesInternal medicineDiabetes mellitusFatty Acids Omega-3medicineHumansAgedDiabetic Retinopathybusiness.industryType 2 Diabetes MellitusPREDIMED studymedicine.diseaseSurgeryOphthalmology030104 developmental biologyDiabetes Mellitus Type 2SeafoodSpainRelative riskDietary SupplementsRetinopatia diabèticabusinessFollow-Up Studies
researchProduct

Plasma Metabolites From Choline Pathway and Risk of Cardiovascular Disease in the PREDIMED (Prevention With Mediterranean Diet) Study.

2017

Background-The relationship between plasma concentrations of betaine and choline metabolism and major cardiovascular disease (CVD) end points remains unclear. We have evaluated the association between metabolites from the choline pathway and risk of incident CVD and the potential modifying effect of Mediterranean diet interventions. Methods and Results-We designed a case-cohort study nested within the PREDIMED (Prevention With Mediterranean Diet) trial, including 229 incident CVD cases and 751 randomly selected participants at baseline, followed up for 4.8 years. We used liquid chromatography-tandem mass spectrometry to measure, at baseline and at 1 year of follow-up, plasma concentrations …

0301 basic medicineMaleTime FactorsMediterranean dietEpidemiologymodelos de riesgos proporcionaleshumanosSistema cardiovascular -- Malaltieséteres de fosfolípidosDisease030204 cardiovascular system & hematologyGut floraDiet MediterraneanCholinechemistry.chemical_compound0302 clinical medicineBetainecardiovascular diseaseRisk FactorsTandem Mass Spectrometryestudios prospectivosmetabolómicaCholineProspective StudiesTrimethylamine-n-oxidemediana edadOriginal ResearchDiet and Nutritionmetilaminas2. Zero hungerAged 80 and overChromatographyancianoCholine metabolismbiologydietaresultado del tratamientoIncidencePhospholipid Ethersdistribución de la ji al cuadradoMiddle AgedCardiovascular disease3. Good healthPrimary PreventioncolinaTreatment OutcomeCardiovascular Diseasesespectrometría de masas en tándemPlasma concentrationProfileFemaleCardiology and Cardiovascular Medicinefosforilcolinamedicine.medical_specialtyPhosphorylcholineestudios de casos y controlesenfermedades cardiovascularesGut microbiotaincidencia03 medical and health sciencesMethylaminesfactores de tiempoInternal medicineMediterranean dietOxidationmedicinefactores de riesgoHumansMetabolomicsanálisis multifactorialDieta -- Mediterrània Regió de lacromatografíaAgedProportional Hazards ModelsChi-Square Distributiongut microbiotabusiness.industrybetaínaPlasma sanguiniLifestylebiology.organism_classificationPredimedDietBetainePhosphatidylcholine030104 developmental biologyEndocrinologychemistrySpainCase-Control StudiesMultivariate AnalysisbusinessBiomarkersChromatography Liquid
researchProduct

Uric acid treatment after stroke modulates the Krüppel-like factor 2-VEGF-A axis to protect brain endothelial cell functions: Impact of hypertension

2019

Uric acid (UA) is a promising protective treatment in ischaemic stroke, but the precise molecular targets underlying its in vivo beneficial actions remain unclear. High concentrations of UA inhibit angiogenesis of cultured endothelial cells via Krüppel-like factor 2 (KLF)-induced downregulation of vascular endothelial growth factor (VEGF), a pro-angiogenic mediator that is able to increase blood–brain barrier (BBB) permeability in acute stroke. Here, we investigated whether UA treatment after ischaemic stroke protects brain endothelial cell functions and modulates the KLF2-VEGF-A axis. Transient intraluminal middle cerebral artery (MCA) occlusion/reperfusion was induced in adult male sponta…

0301 basic medicineMaleVascular Endothelial Growth Factor AVascular endothelial growth factor-AAngiogenesisBiochemistryRats Inbred WKYAntioxidantschemistry.chemical_compound0302 clinical medicineRats Inbred SHRIschaemic strokeEvans BlueBlood-brain barrierBrainKrüppel-like factor 2Vascular endothelial growth factorEndothelial stem cellStrokeVascular endothelial growth factor Amedicine.anatomical_structureNeuroprotective AgentsTreatment OutcomeBlood-Brain Barrier030220 oncology & carcinogenesisHypertensioncardiovascular systemmedicine.symptommedicine.medical_specialtyKruppel-Like Transcription FactorsBrain damageBlood–brain barrierNeuroprotectionCell Line03 medical and health sciencesDouble-Blind MethodInternal medicinemedicineAnimalsHumanscardiovascular diseasesPharmacologybusiness.industryRatsUric Acid030104 developmental biologyEndocrinologychemistryEndothelium VascularAngiogenesisbusinessBiomarkers
researchProduct

Impact of elosulfase alfa in patients with morquio A syndrome who have limited ambulation: An open-label, phase 2 study.

2017

Efficacy and safety of elosulfase alfa enzyme replacement therapy (ERT) were assessed in an open-label, phase 2, multi-national study in Morquio A patients aged ≥5 years unable to walk ≥30 meters in the 6-min walk test. Patients received elosulfase alfa 2.0 mg/kg/week intravenously for 48 weeks. Efficacy measures were functional dexterity, pinch/grip strength, mobility in a modified timed 25-foot walk, pain, quality of life, respiratory function, and urine keratan sulfate (KS). Safety/tolerability was also assessed. Fifteen patients received elosulfase alfa, three patients discontinued ERT due to adverse events (two were grade 3 drug-related adverse events, the other was not drug-related), …

0301 basic medicineMaleWalkingchemistry.chemical_compoundGrip strengthGALNS protein0302 clinical medicineElosulfase alfaQuality of lifeActivities of Daily LivingRespiratory functionFunctional abilityChildGenetics (clinical)education.field_of_studyMucopolysaccharidosis IVChondroitinsulfatases3. Good healthRespiratory Function TestsTreatment OutcomeTolerability6.1 PharmaceuticalsOriginal ArticleFemalePatient Safetyphysical enduranceGALNS protein human [supplementary concept]Adultsafetymedicine.medical_specialtyAdolescentClinical Trials and Supportive ActivitiesPopulationClinical Sciences03 medical and health sciencesYoung Adultmobility limitationClinical ResearchInternal medicinemedicineGeneticsHumansEnzyme Replacement TherapyAdverse effecteducationhuman [supplementary concept]Exercisebusiness.industryEvaluation of treatments and therapeutic interventionsOriginal Articles030104 developmental biologychemistryKeratan SulfateQuality of LifeSelf Reportbusiness030217 neurology & neurosurgeryBiomarkers
researchProduct